Physician profile
Mary Bourang
NPI 1316622251
$4,136.25
in general payments reported to CMS, 2019-2025
28 companies · $877 in 2025
The $877 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.29 · 2023: $953 · 2024: $2,285 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,588 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,588.26 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $247.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,439.09 | 2023-2025 | |
| Seagen INC. | $189.28 | 2023-2025 | Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $185.36 | 2022-2025 | |
| Pfizer INC. | $176.90 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.26 | 2023-2025 | Alunbrig, Fruzaqla |
| Sobi, INC | $151.80 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $89.01 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $75.76 | 2024 | |
| Lilly USA, LLC | $69.21 | 2023-2024 | Jaypirca, Verzenio |
| Agios Pharmaceuticals, INC. | $63.09 | 2025 | Pyrukynd |
| Celgene Corporation | $62.65 | 2024-2025 | Pomalyst, Reblozyl |
| Incyte Corporation | $47.61 | 2023-2024 | Monjuvi, Jakafi |
| Janssen Biotech, INC. | $47.09 | 2025 | Rybrevant |
| Puma Biotechnology, INC. | $44.61 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $33.42 | 2024 | Xpovio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $32.65 | 2024 | |
| Abbvie INC. | $29.54 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $27.07 | 2024 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.50 | 2024 | Gilotrif |
| Array Biopharma INC | $26.44 | 2025 | Braftovi, Mektovi |
| Adaptive Biotechnologies Corporation | $25.88 | 2025 | Clonoseq |
| Daiichi Sankyo INC. | $22.64 | 2024 | Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $21.85 | 2023 | Imbruvica |
| Alexion Pharmaceuticals, INC. | $20.13 | 2023 | Ultomiris |
| Shield Therapeutics INC | $19.35 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $18.53 | 2023 | Lynparza |
| Sumitomo Pharma America, INC. | $16.13 | 2024 | Orgovyx |
| Mirati Therapeutics, INC. | $14.40 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Bourang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.